NICE approves dexamethasone for macular oedema
Dexamethasone has been approved in England and Wales for the treatment of patients with macular oedema by the National Institute for Health and Clinical Excellence.
New guidance published this week (27 July 2011) recommends dexamethasone (Ozurdex; Allergan) intravitreal implant injected into the affected eye once every 6 months, for the treatment of macular oedema following central retinal vein occlusion.
The guidance also recommends dexamethasone following branch retinal vein occlusion when treatment with laser photocoagulation has not been beneficial or has not been considered suitable because of the extent of macular haemorrhage.
Although dexamethasone costs more than the current most common treatment bevacizumab, the benefits to vision outweigh the cost, says NICE.
Citation: The Pharmaceutical Journal URI: 11081421
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com